Neuroprotective effect of newly synthesized 4-aminopyridine derivatives on cuprizone-induced demyelination in mice-a behavioral and immunohistochemical study.
4-aminopyridine
Cuprizone
Demyelinating diseases
Memory
Multiple sclerosis
Journal
Amino acids
ISSN: 1438-2199
Titre abrégé: Amino Acids
Pays: Austria
ID NLM: 9200312
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
29
12
2020
accepted:
30
06
2021
pubmed:
10
7
2021
medline:
31
12
2021
entrez:
9
7
2021
Statut:
ppublish
Résumé
The aim of this study was to assess the effect of newly synthesized derivatives of 4-aminopyridine (4-AP) on cuprizone-induced model of brain demyelination in mice. 4-AP is already approved for the treatment of walking difficulties in patients with multiple sclerosis. The model of demyelination was carried out by the administration of cuprizone to the drinking water of the experimental mice. Besides cuprizone, 4-AP derivatives and 4-AP were administered to the groups in order to assess their protective effect on the demyelination. We used immunohistochemistry for visualization of changes in corpus callosum. Memory storage processes were also assessed with the passive avoidance test on the last two days of the experiment. The experimental mice treated with compounds 4b and 4c increased significantly their latency time on the second day in comparison to the control group which indicated an improved memory process. The number of mature oligodendrocytes in the groups treated with compounds 4b, 4c and 4-AP is closer to those in the control group. The results of our studies showed that the newly synthesized compounds 4b and 4c reverse the effect of cuprizone. These groups also showed increased latency time in the passive avoidance test in comparison to the control group.
Identifiants
pubmed: 34240251
doi: 10.1007/s00726-021-03035-2
pii: 10.1007/s00726-021-03035-2
doi:
Substances chimiques
Neuroprotective Agents
0
Cuprizone
5N16U7E0AO
4-Aminopyridine
BH3B64OKL9
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1279-1286Subventions
Organisme : Medical University of Sofia, Bulgaria
ID : Project №82/23.04.2019
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.
Références
Acs P, Selak MA, Komoly S, Kalman B (2013) Distribution of oligodendrocyte loss and mitochondrial toxicity in the cuprizone-induced experimental demyelination model. J Neuroimmunol 262:128–131. https://doi.org/10.1016/j.jneuroim.2013.06.012
doi: 10.1016/j.jneuroim.2013.06.012
pubmed: 23890807
Asano M, Wakabayashi T, Ishikawa K, Kishimoto H (1978) Mechanism of the formation of megamitochondria by copper-chelating agents. IV. Role of fusion phenomenon in the cuprizone-induced megamitochondrial formation. Acta Pathol Jpn 28:205–213. https://doi.org/10.1111/j.1440-1827.1978.tb00532.x
doi: 10.1111/j.1440-1827.1978.tb00532.x
pubmed: 676744
Bacia A, Wollmann R, Soliven B (2004) K+ channel blockade impairs remyelination in the cuprizone model. Glia 48:156–165. https://doi.org/10.1002/glia.20067
doi: 10.1002/glia.20067
pubmed: 15378653
Bakker DA, Ludwin SK (1987) Blood-brain barrier permeability during cuprizone-induced demyelination. Implications for the pathogenesis of immune-mediated demyelinating diseases. J Neurol Sci 78:125–137. https://doi.org/10.1016/0022-510X(87)90055-4
doi: 10.1016/0022-510X(87)90055-4
pubmed: 3553434
Biancotti JC, Kumar S, de Vellis J (2008) Activation of inflammatory response by a combination of growth factors in cuprizone-induced demyelinated brain leads to myelin repair. Neurochem Res 33:2615–2628. https://doi.org/10.1007/s11064-008-9792-8
doi: 10.1007/s11064-008-9792-8
pubmed: 18661234
Blakemore W (1972) Observations on oligodendrocyte degeneration, the resolution of status spongiosus and remyelination in cuprizone intoxication in mice. J Neurocytol 1:413–426. https://doi.org/10.1007/BF01102943
doi: 10.1007/BF01102943
pubmed: 8530973
Carlton WW (1969) Spongiform encephalopathy induced in rats and guinea pigs by cuprizone. Exp Mol Pathol 10:274–287. https://doi.org/10.1016/0014-4800(69)90057-4
doi: 10.1016/0014-4800(69)90057-4
pubmed: 5788627
Dietrich M, Koska V, Hecker C et al (2020) Protective effects of 4-aminopyridine in experimental optic neuritis and multiple sclerosis. Brain 143(4):1127–1142. https://doi.org/10.1093/brain/awaa062
doi: 10.1093/brain/awaa062
pubmed: 32293668
Fischbach F, Nedelcu J, Leopold P, Zhan J, Clarner T, Nellessen L, Beißel C, van Heuvel Y, Goswami A, Weis J, Denecke B, Schmitz C, Hochstrasser T, Nyamoya S, Victor M, Beyer C, Kipp M (2019) Cuprizone-induced graded oligodendrocyte vulnerability is regulated by the transcription factor DNA damage-inducible transcript 3. Glia 67:263–276. https://doi.org/10.1002/glia.23538
doi: 10.1002/glia.23538
pubmed: 30511355
Franco-Pons N, Torrente M, Colomina MT, Vilella E (2007) Behavioral deficits in the cuprizone-induced murine model of demyelination/remyelination. Toxicol Lett 169:205–213. https://doi.org/10.1016/j.toxlet.2007.01.010
doi: 10.1016/j.toxlet.2007.01.010
pubmed: 17317045
Gallo V, Zhou JM, McBain CJ, Wright P, Knutson PL, Armstrong RC (1996) Oligodendrocyte progenitor cell proliferation and lineage progression are regulated by glutamate receptor-mediated K-channel block. J Neurosci 16:2659–2670. https://doi.org/10.1523/JNEUROSCI.16-08-02659.1996
doi: 10.1523/JNEUROSCI.16-08-02659.1996
pubmed: 8786442
pmcid: 6578780
Gudi V, Gingele S, Skripuletz T, Stangel M (2014) Glial response during cuprizone-induced de- and remyelination in the CNS: lessons learned. Front Cell Neurosci 8:73. https://doi.org/10.3389/fncel.2014.00073
doi: 10.3389/fncel.2014.00073
pubmed: 24659953
pmcid: 3952085
Hiremath MM, Saito Y, Knapp GW, Ting JP-Y, Suzuki K, Matsushima GK (1998) Microglial/macrophage accumulation during cuprizone-induced demyelination in C57BL/6 mice. J Neuroimmunol 92:38–49. https://doi.org/10.1016/S0165-5728(98)00168-4
doi: 10.1016/S0165-5728(98)00168-4
pubmed: 9916878
Judge SI, Bever CT Jr (2006) Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharmacol Ther 111:224–259. https://doi.org/10.1016/j.pharmthera.2005.10.006
doi: 10.1016/j.pharmthera.2005.10.006
pubmed: 16472864
Kashani IR, Chavoshi H, Pasbakhsh P, Hassani M, Omidi A, Mahmoudi R, Beyer C, Zendedel A (2017) Protective effects of erythropoietin against cuprizone-induced oxidative stress and demyelination in the mouse corpus callosum. Iran J Basic Med Sci 20:886–893. https://doi.org/10.22038/ijbms.2017.9110
doi: 10.22038/ijbms.2017.9110
pubmed: 29085580
pmcid: 5651474
Kondo A, Nakano T, Suzuki K (1987) Blood-brain barrier permeability to horseradish peroxidase in twitcher and cuprizone-intoxicated mice. Brain Res 425:186–190. https://doi.org/10.1016/0006-8993(87)90499-9
doi: 10.1016/0006-8993(87)90499-9
pubmed: 3427420
Kostadinova I, Danchev N (2019) 4-aminopyridine—the new old drug for the treatment of neurodegenerative diseases. Pharmacia 66:67–74. https://doi.org/10.3897/pharmacia.66.e35976
doi: 10.3897/pharmacia.66.e35976
Kostadinova I, Landzhov B, Danchev N, Vezenkov L, Oskar A (2020) Effect of 4- aminopyridine and newly synthesized 4-aminopyridine derivatives on cuprizone-induced demyelination of corpus callosum in mice. C R Acad Bulg Sci 73:1137–1142. https://doi.org/10.7546/CRABS.2020.08.13
doi: 10.7546/CRABS.2020.08.13
Love S (1988) Cuprizone neurotoxicity in the rat: morphologic observations. J Neurol Sci 84:223–237. https://doi.org/10.1016/0022-510X(88)90127-X
doi: 10.1016/0022-510X(88)90127-X
pubmed: 2837540
Mason JL, Ye P, Suzuki K, D’Ercole AJ, Matsushima GK (2000) Insulin like growth factor-1 inhibits mature oligodendrocyte apoptosis during primary demyelination. J Neurosci 20:5703–5708. https://doi.org/10.1523/JNEUROSCI.20-15-05703.2000
doi: 10.1523/JNEUROSCI.20-15-05703.2000
pubmed: 10908609
pmcid: 6772563
Matsushima GK, Morell P (2001) The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol 11:107–116. https://doi.org/10.1111/j.1750-3639.2001.tb00385.x
doi: 10.1111/j.1750-3639.2001.tb00385.x
pubmed: 11145196
Morell P, Barrett CV, Mason JL, Toews AD, Hostettler JD, Knapp GW, Matsushima GK (1998) Gene expression in the brain during cuprizone-induced demyelination and remyelination. Mol Cell Neurosci 12:220–227. https://doi.org/10.1006/mcne.1998.0715
doi: 10.1006/mcne.1998.0715
pubmed: 9828087
Moriguchi K, Miyamoto K, Fukumoto Y, Kusunoki S (2018) 4-Aminopyridine ameliorates relapsing remitting experimental autoimmune encephalomyelitis in SJL/J mice. J Neuroimmunol 323:131–135. https://doi.org/10.1016/j.jneuroim.2018.08.007
doi: 10.1016/j.jneuroim.2018.08.007
pubmed: 30139717
Pandit L, Murthy JM (2011) Treatment of multiple sclerosis. Ann Indian Acad Neurol 14:65–69. https://doi.org/10.4103/0972-2327.83094
doi: 10.4103/0972-2327.83094
Paxinos G, Franklin KBJ (2001) The mouse brain in stereotaxic coordinates, 2nd edn. Academic Press, San Diego
Praet J, Guglielmetti C, Berneman Z, Van der Linden A, Ponsaerts P (2014) Cellular and molecular neuropathology of the cuprizone mouse model: clinical relevance for multiple sclerosis. Neurosci Biobehav Rev 47:485–505. https://doi.org/10.1016/j.neubiorev.2014.10.004
doi: 10.1016/j.neubiorev.2014.10.004
pubmed: 25445182
Shrager P, Novakovic SD (1995) Control of myelination, axonal growth, and synapse formation in spinal cord explants by ion channels and electrical activity. Dev Brain Res 88:68–78. https://doi.org/10.1016/0165-3806(95)00081-N
doi: 10.1016/0165-3806(95)00081-N
Strijbis EM, Bijvank JAN, Killestein J (2020) 4-Aminopyridine is not just a symptomatic therapy, it has a neuroprotective effect—yes. Mult Scler 26(11):1309–1310. https://doi.org/10.1177/1352458520923951
doi: 10.1177/1352458520923951
pubmed: 32628062
pmcid: 7543014
Tandler B, Hoppel CL (1975) The failure of supplemental dietary copper to prevent cuprizone-induced alterations in mouse hepatocytes. Beitr Pathol 156:56–64. https://doi.org/10.1016/S0005-8165(75)80085-0
doi: 10.1016/S0005-8165(75)80085-0
pubmed: 1180820
Venturini G (1973) Enzymic activities and sodium, potassium and copper concentrations in mouse brain and liver after cuprizone treatment in vivo. J Neurochem 21:1147–1151. https://doi.org/10.1111/j.1471-4159.1973.tb07569.x
doi: 10.1111/j.1471-4159.1973.tb07569.x
pubmed: 4357499
Vezenkov L, Zaharieva D, Danchev N, Vassilev N, Bakalova A, Ivanov T (2014) Synthesis of 4-aminopyridine derivatives comprising peptide moiety designed for prevention and treatment of Alzheimer’s disease and multiple sclerosis. In: Proceedings of the 33rd European peptide symposium, pp 200–201
Wagner T, Rafael J (1977) Biochemical properties of liver megamitochondria induced by chloramphenicol or cuprizone. Exp Cell Res 107:1–13. https://doi.org/10.1016/0014-4827(77)90379-2
doi: 10.1016/0014-4827(77)90379-2
pubmed: 193704
Wakabayashi T, Asano M, Ishikawa K, Kishimoto H (1978) Mechanism of the formation of megamitochondria by copper-chelating agents. V. Further studies on isolated megamitochondria. Acta Pathol Jpn 28:215–223. https://doi.org/10.1111/j.1440-1827.1978.tb00533.x
doi: 10.1111/j.1440-1827.1978.tb00533.x
pubmed: 209665
Waubant E, Lucas R, Mowry E, Graves J, Olsson T, Alfredsson L, Langer-Gould A (2019) Environmental and genetic risk factors for MS: an integrated review. Ann Clin Transl Neurol 6:1905–1922. https://doi.org/10.1002/acn3.50862
doi: 10.1002/acn3.50862
pubmed: 31392849
pmcid: 6764632
Xu C, Bailly-Maitre B, Reed JC (2005) Endoplasmic reticulum stress: cell life and death decisions. J Clin Invest 115:2656–2664. https://doi.org/10.1172/JCI26373
doi: 10.1172/JCI26373
pubmed: 16200199
pmcid: 1236697